Our understanding of the complex patterns of inflammation underlying asthma pathogenesis has informed the development of antibody-based biological therapies that target the T2 cytokines, IL-4, IL-5, and IL-13, in adults [21,22,23] and in adolescents and children with refractory asthma [24]. This evidence concerns the gene IL4 and asthma.